Abstract: The present invention relates generally to the fields of pharmacology, and particularly to a method for treating inflammation, particularly inflammation of the respiratory system. The invention provides a method to reduce or ameliorate inflammation, by administering an effective amount of a protein factor originally isolated from thymic tissue, and referred to as T4 immune stimulating factor (TISF).

Abstract: Methods and apparatus are provided to resolve analytes within a fluid path using isoelectric focusing, gel electrophoresis, or other separation means. Materials within the fluid path that are compatible with these separation means are used to attach resolved analytes to the wall of the fluid path. Attachment results from a triggerable event such as photoactivation, thermal activation, or chemical activation. In accordance with a further aspect of the present invention, the material in the capillary may also be disrupted, by either the triggerable event or a subsequent event such as melting or photocleavage. Thus, an open lumen or porous structure may be created within the fluid path, allowing unbound analyte materials to be washed from the fluid path, and detection agents to be washed into the fluid path. The separation-compatible materials may be polymerizable monomers, gels, entangled polymers or other materials.

Abstract: Methods for detecting one or more analytes, such as a protein, in a fluid path are provided. The methods include resolving, immobilizing and detecting one or more analytes in a fluid path, such as a capillary. Also included are devices and kits for performing such assays.

Abstract: Methods for detecting one or more analytes, such as a protein, in a fluid path are described herein. In some embodiments a method includes resolving one or more analytes in a fluid path, such as, for example, a capillary. After the one or more analytes are resolved, the one or more analytes are bound to the fluid path upon activation of one or more triggerable agents disposed within the fluid path. The one or more analytes that are bound to the fluid path are detected within the fluid path.

Abstract: Methods for detecting one or more analytes, such as a protein, in a fluid path are provided. The methods include resolving, immobilizing and detecting one or more analytes in a fluid path, such as a capillary. Also included are devices and kits for performing such assays.

Abstract: Methods for detecting one or more analytes, such as a protein, in a fluid path are provided. The methods include resolving, immobilizing and detecting one or more analytes in a fluid path, such as a capillary. Also included are devices and kits for performing such assays.

Abstract: The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF or of a compound that stimulates CD4+ cells like TISF does. In one embodiment, TISF that originates from a mammalian species is administered to a mammalian subject diagnosed as having a deficiency in one or more types of blood cells.

Abstract: Methods for detecting one or more analytes, such as a protein, in a fluid path are provided. The methods include resolving, immobilizing and detecting one or more analytes in a fluid path, such as a capillary. Also included are devices and kits for performing such assays.

Abstract: T4 Immune Stimulating Factor (TISF) selectively induces aberrant T-cells to initiate apoptosis. TISF and peptides that are related to TISF (TISF peptides) are therefore useful for the treatment of disorders characterized by aberrant production, development, or activity of T-cells or other cells of hematopoietic origin. This invention relates to methods of using TISF or a TISF peptide to treat such conditions, compositions containing TISF or a TISF peptide for use in such treatments, and use of TISF or a TISF peptide for the manufacture of pharmaceuticals.

Abstract: The present invention relates generally to the fields of pharmacology, and particularly to a method for treating inflammation, particularly inflammation of the respiratory system. The invention provides a method to reduce or ameliorate inflammation, by administering an effective amount of a protein factor originally isolated from thymic tissue, and referred to as T4 immune stimulating factor (TISF).

Abstract: The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF or of a compound that stimulates CD4+ cells like TISF does. In one embodiment, TISF that originates from a mammalian species is administered to a mammalian subject diagnosed as having a deficiency in one or more types of blood cells.

Abstract: The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF or of a compound that stimulates CD4+ cells like TISF does. In one embodiment, TISF that originates from a mammalian species is administered to a mammalian subject diagnosed as having a deficiency in one or more types of blood cells.

Abstract: The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF or of a compound that stimulates CD4+ cells like TISF does. In one embodiment, TISF that originates from a mammalian species is administered to a mammalian subject diagnosed as having a deficiency in one or more types of blood cells.